GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years
Portfolio Pulse from Vandana Singh
GSK plc (NYSE:GSK) announced positive long-term efficacy data for its Shingrix vaccine from the ZOSTER-049 trial, showing sustained efficacy against shingles in adults over 50 for over a decade. The trial included over 7,000 participants, demonstrating vaccine efficacy rates of 79.7% in adults aged 50+ and 73.1% in those 70+ from six to 11 years post-vaccination. Additionally, GSK reported results from the EAGLE-1 Phase 3 trial of gepotidacin, an oral antibiotic for gonorrhea, showing non-inferiority to the standard combination therapy. GSK shares are down 1.15% in premarket trading.
April 17, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
GSK announced positive long-term efficacy data for Shingrix and promising results for gepotidacin, an oral antibiotic for gonorrhea. Shares are down 1.15% in premarket trading.
The positive trial results for both Shingrix and gepotidacin indicate strong potential for future revenue growth and market expansion for GSK. However, the immediate negative reaction in premarket trading suggests short-term investor concerns or profit-taking. The long-term efficacy of Shingrix supports its competitive position in the vaccine market, and gepotidacin's success in trials could address a significant need in antibiotic treatment. Despite the positive news, the short-term stock price movement is negative, possibly due to broader market conditions or expectations already priced in.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100